Many diseases remain undruggable with current therapeutic modalities. Nearly all diseases are driven by genetic mutations. NeuBase is advancing first-in-class precision genetic medicines to “drug the genome” and address disease at its base level to help millions of patients, who currently have no therapeutic options.

NeuBase needed to update its website based on their technology to address several diseases on its PATrOL platform. For each of their three pipeline elements, we created mechanism of action diagrams to explain how their drug candidates would interact with targeted mutations. The site also included a patient portal for resources to help those afflicted with their targeted diseases in their journey and a publication library to support their evidence.